Literature DB >> 20847518

Intensive insulin therapy during cardiovascular surgery.

Shinji Kawahito1, Hiroshi Kitahata, Tetsuya Kitagawa, Shuzo Oshita.   

Abstract

Recent evidence in the fields of surgery, emergency and critical care medicine indicates that strict glycemic control results in lower mortality. Hyperglycemia occurs frequently in patients with and without diabetes during cardiovascular surgery, especially during cardiopulmonary bypass. However, strict glucose control is difficult to achieve during cardiovascular procedures. To establish effective intensive insulin therapy during cardiovascular surgery, we conduct continuous blood glucose monitoring and employ automatic control by using an artificial endocrine pancreas (the STG-22, Nikkiso, Tokyo, Japan). In this review, we will outline the present status and problems of conventional glycemic control for perioperative cardiovascular surgery and introduce the new perioperative blood glucose management method that we are testing now. We will also discuss the importance of perioperative glycemic control for cardiovascular surgery as well as future prospects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847518     DOI: 10.2152/jmi.57.191

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  2 in total

1.  Accuracy and reliability of continuous blood glucose monitoring during pediatric cardiopulmonary bypass.

Authors:  Shinji Kawahito; Naoji Mita; Tomohiro Soga; Shusuke Yagi; Nami Kakuta; Shiho Satomi; Hiroyuki Kinoshita; Kazumi Takaishi; Tetsuya Kitagawa; Hiroshi Kitahata
Journal:  J Artif Organs       Date:  2019-06-24       Impact factor: 1.731

2.  Anti-inflammatory effects of perioperative intensive insulin therapy during cardiac surgery with cardiopulmonary bypass.

Authors:  Akira Hasegawa; Hideo Iwasaka; Satoshi Hagiwara; Hironori Koga; Rie Hasegawa; Kyosuke Kudo; Junya Kusaka; Takayuki Noguchi
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.